# Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

> **NCT01855711** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 32 (actual)

## Conditions studied

- Irritable Colon

## Interventions

- **DRUG:** GR68755 (Alosetron hydrochloride) 1 mg tablet

## Key facts

- **NCT ID:** NCT01855711
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-18
- **Primary completion:** 2005-05-10
- **Final completion:** 2005-05-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855711, "Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01855711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*